These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 29016839)

  • 1. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
    Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
    Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
    Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
    Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
    Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
    J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma.
    Nuechterlein N; Shapiro LG; Holland EC; Cimino PJ
    Acta Neuropathol Commun; 2021 Dec; 9(1):191. PubMed ID: 34863298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
    Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
    Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.